Patents by Inventor Lori Friedman

Lori Friedman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human RRP sequences and methods of use
    Patent number: 6924117
    Abstract: Rhomboid Related Proteins (RRPs), involved in the EGFR signaling pathway, are provided. Transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide or a gene effecting the expression of an RRP polypeptide, along with methods of modulating the interaction of RRP proteins with their pathway members, and methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, such as RRP-specific antibodies and small molecules identified in high throughput screens, are also provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: August 2, 2005
    Assignee: Exelixis, Inc.
    Inventors: Mario N. Lioubin, Lori Friedman, Marcia Belvin, Jeffery S. Larson, Changyou Chen, Stephanie A. Robertson, Wen Shi, Jocelyn Chan, Danxi Li
  • Dgks as modifiers of the p53 pathwha and methods of use
    Publication number: 20050112568
    Abstract: Human DGK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53,comprising screening for agents that modulate the activity of DKG are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: May 26, 2005
    Inventors: Lori Friedman, Gregory Plowman, Mercia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Insect p53 tumor suppressor genes and proteins
    Publication number: 20040161827
    Abstract: A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.
    Type: Application
    Filed: February 5, 2004
    Publication date: August 19, 2004
    Inventors: Andrew Roy Buchman, Darren Mark Platt, Michael Martin Ollmann, Lynn Marie Young, Madelyn Robin Demsky, Kevin Patrick Keegan, Lori Friedman, Casey Kopczynski, Jeffrey S. Larson, Stephanie A. Robertson
  • Insect p53 tumor suppressor genes and proteins
    Patent number: 6762291
    Abstract: A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: July 13, 2004
    Assignee: Exelixis, Inc.
    Inventors: Andrew Roy Buchman, Darren Mark Platt, Michael Martin Ollman, Lynn Marie Young, Madelyn Robin Demsky, Kevin Patrick Keegan, Lori Friedman, Casey Kopczynski, Jeffrey S. Larson, Stephanie A. Robertson
  • SCDs as modifiers of the p53 pathway and methods of use
    Publication number: 20030219795
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Application
    Filed: February 28, 2003
    Publication date: November 27, 2003
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • PDPK1s as modifiers of the p53 pathway and methods of use
    Publication number: 20030215849
    Abstract: Human PDPK1 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PDPK1 are provided.
    Type: Application
    Filed: February 28, 2003
    Publication date: November 20, 2003
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • MARKs as modifiers of the p53 pathway and methods of use
    Publication number: 20030165809
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: September 4, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • RRP sequences and knockout mice and uses thereof
    Publication number: 20030165497
    Abstract: RRP genes are identified as modulators of the p53 or p21 pathway, and thus are therapeutic targets for disorders associated with defective p53 or p21 function. Methods for identifying modulators of p53 or p21, comprising screening for agents that modulate the activity of RRP are provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. mRRP1 knockout mice are also provided.
    Type: Application
    Filed: January 23, 2002
    Publication date: September 4, 2003
    Inventors: Mario N. Lioubin, Lori Friedman, Marcia Belvin, Jeffrey S. Larson, Changyou Chen, Stephanie A. Robertson, Wen Shi, Jocelyn Chan, Danxi Li, Helen Francis-Lang, Gregory D. Plowman, Roel P. Funke, Michael Schoor, Branko Zevnik, Gunther Kauselmann, Hartmut Tintrup
  • MSRAs as modifiers of the p53 pathway and methods of use
    Publication number: 20030165966
    Abstract: Human MSRA genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MSRA are provided.
    Type: Application
    Filed: February 28, 2003
    Publication date: September 4, 2003
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • IGs as modifiers of the p53 pathway and methods of use
    Publication number: 20030087266
    Abstract: Human IG genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of IG are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: May 8, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • CADs as modifiers of the p53 pathway and methods of use
    Publication number: 20030036076
    Abstract: Human CAD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of CAD are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: February 20, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • P5CRs as modifiers of the p53 pathway and methods of use
    Publication number: 20030036078
    Abstract: Human P5CR genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of P5CR are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: February 20, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Stefan Engst
  • HPRP4s as modifiers of the p53 pathway and methods of use
    Publication number: 20030027230
    Abstract: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
    Type: Application
    Filed: August 2, 2002
    Publication date: February 6, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Tak Hung, Helen Francis-Lang, Danxi Li, Roel P. Funke, Michael Costa
  • SLC7s as modifiers of the p53 pathway and methods of use
    Publication number: 20030027188
    Abstract: Human SLC7 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SLC7 are provided.
    Type: Application
    Filed: June 5, 2002
    Publication date: February 6, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • ADSLs as modifiers of the p53 pathway and methods of use
    Publication number: 20030022209
    Abstract: Human ADSL genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of ADSL are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: January 30, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Stefan Engst
  • HADHs as modifiers of the p21 pathway and methods of use
    Publication number: 20030022222
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: January 30, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • Genetic Markers for breast, ovarian, and prostatic cancer
    Patent number: 6512091
    Abstract: Specific BRCA1 mutations, PCR primers and hybridization probes are used in nucleic acid-based methods for diagnostic of inheritable breast cancer susceptibility. Additionally, binding agents, such as antibodies, specific for peptides encoded by the subject BRCA1 mutants are used to identify expression products of diagnostic mutations/rare alleles in patient derived fluid or tissue samples. Compositions with high binding affinity for transcription or translation products of the disclosed BRCA1 mutations and alleles are used in therapeutic intervention. Such products include anti-sense nucleic acids, peptides encoded by the subject nucleic acids, and binding agents such as antibodies, specific for such peptides.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: January 28, 2003
    Assignee: The Regents of the University of California
    Inventors: Mary-Claire King, Lori Friedman, Beth Ostermeyer, Sarah Rowell, Eric Lynch, Csilla Szabo, Ming Lee
  • PRMTs as modifiers of the p53 pathway and methods of use
    Publication number: 20030017489
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Application
    Filed: June 5, 2002
    Publication date: January 23, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • HS2STs as modifiers of the p53 pathway and methods of use
    Publication number: 20030013144
    Abstract: Human HS2ST genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of HS2ST are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: January 16, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • PIBs as modifiers of the p53 pathway and methods of use
    Publication number: 20020192695
    Abstract: Human PIB genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PIB are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: December 19, 2002
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke